SciClone Pharmaceuticals (Holdings) Limited
HKEX:6600.HK
18.72 (HKD) • At close June 20, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|---|---|
Revenue
| 3,155.614 | 2,749.681 | 2,518.474 | 1,918.562 | 1,708.068 | 1,408.869 | 1,212.966 |
Cost of Revenue
| 799.413 | 679.196 | 585.468 | 428.106 | 393.141 | 302.999 | 181.178 |
Gross Profit
| 2,356.201 | 2,070.485 | 1,933.006 | 1,490.456 | 1,314.927 | 1,105.87 | 1,031.788 |
Gross Profit Ratio
| 0.747 | 0.753 | 0.768 | 0.777 | 0.77 | 0.785 | 0.851 |
Reseach & Development Expenses
| 170.679 | 123.86 | 134.389 | 75.42 | 87.688 | 77.463 | 82.665 |
General & Administrative Expenses
| 257.295 | 225.003 | 206.457 | 216.22 | 36.262 | 54.874 | 168.086 |
Selling & Marketing Expenses
| 712.81 | 627.751 | 579.163 | 456.389 | 460.332 | 389.046 | 395.965 |
SG&A
| 970.105 | 852.754 | 785.62 | 672.609 | 496.594 | 443.92 | 564.051 |
Other Expenses
| 0.497 | -12.125 | -25.991 | -12.628 | 75.328 | 0.309 | -0.002 |
Operating Expenses
| 1,099.014 | 964.489 | 894.018 | 735.401 | 659.61 | 576.481 | 803.511 |
Operating Income
| 1,205.106 | 950.604 | 1,058.106 | 834.923 | 650.189 | 494.356 | 260.76 |
Operating Income Ratio
| 0.382 | 0.346 | 0.42 | 0.435 | 0.381 | 0.351 | 0.215 |
Total Other Income Expenses Net
| 12.291 | -10.524 | -32.233 | -18.114 | 10.982 | -34.116 | 32.237 |
Income Before Tax
| 1,217.397 | 940.08 | 1,025.873 | 816.809 | 661.171 | 495.273 | 260.514 |
Income Before Tax Ratio
| 0.386 | 0.342 | 0.407 | 0.426 | 0.387 | 0.352 | 0.215 |
Income Tax Expense
| 95.495 | 84.725 | 102.512 | 63.114 | 46.567 | -39.809 | 240.932 |
Net Income
| 1,121.902 | 855.355 | 923.361 | 753.695 | 614.604 | 535.082 | 19.582 |
Net Income Ratio
| 0.356 | 0.311 | 0.367 | 0.393 | 0.36 | 0.38 | 0.016 |
EPS
| 1.83 | 1.27 | 1.42 | 1.11 | 0.91 | 0.8 | 0.029 |
EPS Diluted
| 1.72 | 1.21 | 1.33 | 1.11 | 0.91 | 0.79 | 0.029 |
EBITDA
| 1,433.536 | 1,176.043 | 1,171.32 | 964.726 | 692.808 | 536.025 | 296.537 |
EBITDA Ratio
| 0.454 | 0.428 | 0.465 | 0.503 | 0.406 | 0.38 | 0.244 |